跳至主要内容
临床试验/NCT00403624
NCT00403624已完成1 期

Clinical Study to Evaluate a Protocol of Oxaliplatin -UFT- Radiotherapy for the Neoadjuvant Treatment Rectal Cancer

Sanofi0 个研究点目标入组 38 人开始时间: 2001年7月1日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
Sanofi
入组人数
38
主要终点
Tumour response

研究概览

简要总结

Primary objective:

- To evaluate the rate of responses to neoadjuvant therapy + radiotherapy

Secondary objective:

- tolerability (toxicity) and time to progression

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •The following information on clinical trials is provided for information purposes only to allow patients and physicians to have an initial discussion about the trial. This information is not intended to be complete information about the trial, to contain all considerations that may be relevant to potential participation in the trial, or to replace the advice of a personal physician or health professional.
  • •Main criteria are listed hereafter:
  • •Inclusion Criteria:
  • •Patients with measurable, histologically proven rectal cancer.
  • •No history of previous malignancy but adequately treated skin / cervical cancer.
  • •Adequate haematological, renal and liver function.

排除标准

  • •No cardiopulmonary insufficiency or coronary disease. No sensory neuropathy prior to study.

结局指标

主要结局

Tumour response

次要结局

  • Disease free and Overall survival ; Adverse events

研究者

发起方
Sanofi
申办方类型
Industry

相似试验